{"schema_version":"secwatch.filing_event.v1","accession":"0001000694-24-000009","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.024113+00:00","generated_at":"2026-06-05T07:51:56.214587+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Novavax Q4 revenue $291M, full-year net loss $545M; guides 2024 revenue $800M-$1B","bullets":["Q4 2023 revenue $291M (down 18% YoY); full-year revenue $984M (down 51% from $2B in 2022).","Full-year 2023 net loss $545M vs $658M in 2022; operating expenses cut 41% ($1.1B reduction).","Cash $584M at Dec 31, 2023, down from $1.3B a year earlier; raised $110M via ATM offerings in Q4.","FY2024 guidance: total revenue $800M-$1B, combined R&D+SG&A $700-$800M; Q1 2024 revenue expected ~$100M.","Announced Gavi settlement; plan to start Phase 3 COVID-flu combo trial in H2 2024 with potential 2026 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001000694-24-000009","json":"https://secwatch.observer/filing/0001000694-24-000009.json","markdown":"https://secwatch.observer/filing/0001000694-24-000009.md","text":"https://secwatch.observer/filing/0001000694-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/nvax-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:51:56.214587+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de8620a2e1e9eb45c8312ed21d13c77ae7634228","claim":"NOVAVAX INC updated its the fourth quarter and twelve months ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 28, 2024, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000100069424000009/0001000694-24-000009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and twelve months ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}